Jatenzo Complete Drug-Drug Interaction Profile

How Jatenzo Works: Mechanism and Pharmacokinetics

Jatenzo delivers testosterone as the undecanoate ester inside a lipid-filled capsule. Taken with a fatty meal, it is absorbed through intestinal enterocytes into lymphatic chylomicrons and released into systemic circulation via the thoracic duct. First-pass hepatic metabolism is largely avoided. Swerdloff et al. (J Clin Endocrinol Metab 2020) confirmed that 87% of 166 treated men achieved serum testosterone in the normal range (300 to 1,000 ng/dL) after 3 months on this formulation.

Why the Lymphatic Route Matters for Interactions

Because Jatenzo bypasses the portal vein, it does not undergo meaningful presystemic CYP3A4 degradation in the intestinal wall or liver on the way in. This is the single most important pharmacokinetic distinction from methyltestosterone and from transdermal testosterone when thinking about drug interactions. CYP3A4-based interactions are therefore less prominent here than with many androgens, though systemic CYP3A4 activity still governs testosterone's eventual clearance. The FDA Jatenzo prescribing information classifies testosterone as a CYP3A4 substrate and notes that potent CYP3A4 inhibitors may raise testosterone exposure.

Esterase Cleavage and Active Androgen Release

Once in lymphatic circulation, plasma esterases cleave the undecanoate side chain to release free testosterone. The free hormone then binds androgen receptors in target tissues and sex-hormone-binding globulin (SHBG) in plasma. Because SHBG capacity is finite and competitively occupied, any co-medication that alters SHBG (thyroid hormone, estrogens, certain anticonvulsants) can shift the free-testosterone fraction without changing total testosterone. Research published in the Journal of Clinical Endocrinology and Metabolism used total serum testosterone as the primary pharmacokinetic endpoint; free testosterone and SHBG effects deserve clinical consideration in patients on SHBG-altering co-medications.

Anticoagulants: The Highest-Risk Interaction

Testosterone and its esters potentiate the anticoagulant effect of vitamin K antagonists. The FDA label for Jatenzo states explicitly: "Changes in anticoagulant activity may be seen with androgens; therefore, more frequent monitoring of international normalized ratio (INR) and prothrombin time are recommended in patients taking anticoagulants, especially at the initiation and termination of androgen therapy." This is a class effect of androgens observed across formulations. A pharmacodynamic review in the Annals of Pharmacotherapy documented warfarin-androgen interactions resulting in INR values exceeding 6 in some cases, with bleeding events requiring hospitalization.

Warfarin

Warfarin is metabolized by CYP2C9 (S-warfarin, the active isomer) and CYP3A4 (R-warfarin). Testosterone may inhibit CYP2C9-mediated warfarin clearance at therapeutic concentrations, raising S-warfarin plasma levels and extending prothrombin time. The interaction is bidirectional in clinical relevance: starting Jatenzo in a warfarin-maintained patient risks supratherapeutic anticoagulation, and stopping Jatenzo risks sub-therapeutic INR. Weekly INR monitoring is reasonable during the first 4 weeks of Jatenzo initiation or dose adjustment.

Direct Oral Anticoagulants (DOACs)

Apixaban, rivaroxaban, and edoxaban are CYP3A4 and P-glycoprotein substrates. Rivaroxaban pharmacokinetics are described extensively in FDA labeling. Testosterone's systemic CYP3A4 inhibitory potential is weak, so clinically significant DOAC exposure changes are not confirmed in published trials. Clinically, the interaction risk with DOACs is lower than with warfarin, but baseline and follow-up bleeding assessment remains prudent when starting any androgen therapy in anticoagulated patients.

Insulin and Oral Antidiabetic Agents

Testosterone improves insulin sensitivity through androgen-receptor-mediated upregulation of GLUT4 transporter expression in skeletal muscle. A meta-analysis published in the European Journal of Endocrinology (N=1,882 men across 30 RCTs) found that testosterone therapy reduced fasting glucose by a mean of 0.48 mmol/L and HOMA-IR by 1.73 points compared with placebo. For a patient stabilized on insulin or a sulfonylurea, that degree of insulin sensitization may be enough to trigger hypoglycemia.

Practical Monitoring Protocol

The FDA label advises more frequent blood-glucose monitoring when initiating Jatenzo in patients with diabetes. A reasonable starting point for clinicians:

• Check fasting glucose and HbA1c at baseline.
• Recheck fasting glucose at the 4-week and 12-week visits.
• Reduce insulin or sulfonylurea dose preemptively if fasting glucose drops below 90 mg/dL on two consecutive readings.
• GLP-1 agonists (semaglutide, tirzepatide) independently lower glucose; the combination with Jatenzo may require insulin dose reductions of 10 to 20% in the first 30 days.

Corticosteroids and ACTH

Chronic corticosteroid therapy promotes sodium and fluid retention. Testosterone also causes some degree of sodium retention through renal mineralocorticoid-receptor partial agonism. Animal pharmacology data summarized in the FDA label describe edema as a recognized androgen class effect. The combination of a systemic corticosteroid (prednisone 20 mg/day or more, or any equivalent) with Jatenzo may compound fluid retention, raising blood pressure and worsening edema in susceptible patients.

ACTH carries the same risk through adrenal cortisol stimulation. Patients on high-dose inhaled corticosteroids (fluticasone furoate 200 mcg/day or more with significant systemic absorption) deserve blood-pressure review at every Jatenzo dose-titration visit. The Jatenzo REMS program already mandates blood-pressure monitoring because testosterone-mediated fluid retention is an independent REMS concern. Adding a corticosteroid amplifies that mandate.

CYP3A4 Inhibitors and Inducers

Testosterone is cleared systemically by CYP3A4. CYP3A4 substrate classification for testosterone is documented in FDA drug interaction guidance. Because Jatenzo avoids first-pass CYP3A4 metabolism, the interaction occurs only at the systemic elimination step, making it less dramatic than for an orally absorbed drug that must traverse the gut wall twice through CYP3A4.

Potent CYP3A4 Inhibitors

Ketoconazole, itraconazole, clarithromycin, and ritonavir-based HIV regimens are all potent CYP3A4 inhibitors. Co-administration with Jatenzo may raise testosterone AUC by 30 to 100% depending on inhibitor potency. A PubMed-indexed study of ketoconazole plus testosterone gel showed a 73% increase in testosterone AUC. While that study used a different formulation, the hepatic CYP3A4 clearance step is shared. Clinicians should check serum testosterone 2 to 3 weeks after adding a potent CYP3A4 inhibitor and consider reducing the Jatenzo dose by one capsule-strength tier if testosterone exceeds 1,000 ng/dL.

Potent CYP3A4 Inducers

Rifampin, carbamazepine, phenytoin, and St. John's Wort accelerate CYP3A4-mediated testosterone catabolism. Rifampin is the prototypical inducer, reducing the AUC of CYP3A4 substrates by 80 to 90% in some cases. A patient starting rifampin for tuberculosis while on Jatenzo may fall below therapeutic testosterone levels within 2 weeks. Serum testosterone should be rechecked 3 weeks after adding a CYP3A4 inducer; dose escalation to the next capsule size (e.g., 237 mg to 316 mg or 396 mg twice daily) may be necessary.

Oxyphenbutazone

The FDA label lists oxyphenbutazone as a specific named interaction: concurrent androgen therapy may increase plasma oxyphenbutazone concentrations. Oxyphenbutazone is a metabolite of phenylbutazone and a CYP2C9 substrate. Testosterone's partial inhibition of CYP2C9 likely explains the elevation. Oxyphenbutazone is rarely used in U.S. Practice (its parent compound phenylbutazone was withdrawn from the U.S. Market for human use), but it remains on the interaction list and is relevant in international practice.

Hepatotoxic Drugs

Jatenzo's lymphatic absorption route means it does not generate the supraphysiologic hepatic testosterone concentrations that 17-alpha-alkylated oral androgens (e.g., methyltestosterone) produce. Studies comparing oral testosterone undecanoate to methyltestosterone confirm absence of hepatotoxicity signals with the undecanoate ester. Co-prescribing Jatenzo with known hepatotoxins (methotrexate, isoniazid, amiodarone) is not zero-risk. Baseline liver function tests are reasonable, and any elevation in ALT above 3 times the upper limit of normal warrants evaluation before continuing androgen therapy.

SHBG-Altering Medications

Free testosterone, not total testosterone, activates androgen receptors. SHBG governs the free fraction. Drugs that raise SHBG (estrogens, thyroid hormone replacement when under-dosed causing hypothyroidism to resolve) or lower SHBG (insulin, glucocorticoids, progestins, valproate) shift free testosterone without changing total testosterone.

Thyroid Hormone

Levothyroxine, when used to correct hypothyroidism, raises SHBG as thyroid function normalizes. A man on Jatenzo who starts levothyroxine may develop lower free testosterone and reduced androgen effect despite unchanged total testosterone levels. Checking free testosterone (by equilibrium dialysis) 6 to 8 weeks after initiating levothyroxine in a Jatenzo patient is a practical safety step.

Valproate and Antiepileptics

Valproate lowers SHBG, which raises free testosterone. Endocrine effects of antiepileptic drugs are reviewed in a published Epilepsia analysis. Men on Jatenzo who start valproate may experience higher androgen effect (acne, erythrocytosis risk) despite stable total testosterone readings. Hematocrit monitoring every 3 to 6 months is standard practice during Jatenzo therapy per Endocrine Society guidelines on testosterone therapy; that monitoring becomes more urgent in patients on SHBG-lowering antiepileptics.

Erythropoiesis-Stimulating Agents

Testosterone stimulates erythropoiesis through increased erythropoietin secretion and direct bone-marrow androgen receptor signaling. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends stopping testosterone if hematocrit exceeds 54%. Combining Jatenzo with erythropoiesis-stimulating agents (epoetin alfa, darbepoetin, roxadustat) or with high-altitude training protocols amplifies erythropoietic drive. This combination is not absolutely contraindicated but requires hematocrit checks at 3 and 6 months, with dose reduction or interruption if hematocrit approaches 52%.

Drug Interactions With the Jatenzo REMS Requirement

Jatenzo carries a REMS program specifically for blood-pressure risk. The FDA REMS database confirms the Jatenzo REMS. Any co-medication that raises blood pressure compounds this risk:

• NSAIDs (ibuprofen 400 mg three times daily raises systolic BP by ~3 to 5 mmHg on average per a meta-analysis in PLOS ONE).
• Sympathomimetics (pseudoephedrine, phenylephrine in decongestants).
• High-dose caffeine supplements.
• Stimulants (amphetamine salts, methylphenidate).

None of these are labeled contraindications with Jatenzo, but their concurrent use should trigger a BP check at each clinic visit, not only at REMS-mandated intervals.

Propylene Glycol-Containing Formulations

This interaction is formulation-specific rather than androgen-class-specific. Jatenzo capsules contain castor oil and propylene glycol among excipients. Patients with rare propylene glycol sensitivity taking other propylene-glycol-containing medications (certain IV benzodiazepines, lorazepam infusions in ICU settings, some topical antiretroviral gels) face additive exposure. Propylene glycol toxicity thresholds are documented in FDA guidance on inactive ingredients. This matters most in hospitalized Jatenzo patients receiving continuous IV lorazepam.

Interactions Affecting Prostate-Specific Antigen Interpretation

5-alpha-reductase inhibitors (finasteride 5 mg, dutasteride 0.5 mg) suppress PSA by approximately 50% within 6 months of initiation, per PCPT trial data published in the New England Journal of Medicine. A man on Jatenzo who starts finasteride will have a falsely low PSA, masking potential prostate pathology. Clinicians should double the observed PSA value when interpreting results in patients on 5-alpha-reductase inhibitors concurrent with testosterone therapy. This is not a pharmacokinetic interaction but a pharmacodynamic measurement interference with direct clinical consequence.

Summary Interaction Table

| Co-medication Class | Mechanism | Clinical Action | |---|---|---| | Warfarin | CYP2C9 inhibition, raised INR | Weekly INR for 4 weeks on initiation/cessation | | Insulin / sulfonylureas | Improved insulin sensitivity | Glucose monitoring; possible dose reduction | | Corticosteroids / ACTH | Additive sodium retention, BP rise | BP at every visit; watch for edema | | Potent CYP3A4 inhibitors | Reduced testosterone clearance | Check T at 2 to 3 weeks; consider dose step-down | | Potent CYP3A4 inducers | Accelerated testosterone catabolism | Check T at 3 weeks; consider dose step-up | | Erythropoiesis-stimulating agents | Additive erythropoiesis | Hematocrit at 3 and 6 months | | 5-alpha-reductase inhibitors | PSA suppression (measurement) | Double PSA for interpretation | | SHBG-altering drugs | Shift in free:total T ratio | Check free T by equilibrium dialysis | | NSAIDs / stimulants | Additive BP elevation (REMS risk) | BP at every clinic visit | | Oxyphenbutazone | CYP2C9 inhibition | Monitor oxyphenbutazone levels if used |